APOC3 and type 2 diabetes mellitus: Apo-CIII glycosylation was available for 2,318 participants in the DiaGene Study; the participants’ mean age was 65.3 (SD 9.5) years, 51% was female, the median body mass index (BMI) was 28.0 (IQR 25.2 to 31.6) kg/m2, 68% had type 2 diabetes, and 48% used lipid-lowering therapy.